Dr. Jonathan Kay with changes in ICD coding from ICD-9 to ICD-10. And we just got an ICD code for nr-axSpA! It's M46.80 https://t.co/JAlF4ERoHr #ACR20 https://t.co/lmElQVtv35

• Non-Radiographic Axial Spondyloarthritis Recognized with ICD-10 Code - The Rheu…

Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the classification of axSpA. Do you think it’s time to change our nomenclature and classification criteria? #ACR20 @RheumNow https://t.co/YJcvLKnyFy

Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS criteria. This likely won’t be adopted in the US for several years. #ACR20 ⁦@RheumNow⁩ https://t.co/oDhs1EHSTP

Do you know Walter Bauer, MD #ACR20? Well, I didn't either! Dr. M. Weinblatt taught me that Dr. Bauer was an important US rheumatologist who did NOT believe AS was a separate disease entity from RA! It wasn't until his death that the college recognized both separately! @RheumNow

Listen to part I of our #ACR20 Day 1 recap. Listen through the link below or find us on Apple podcasts. https://t.co/W6EMQiF9Rf https://t.co/R1ieCFnIxz

• https://bit.ly/352dlRc

Gender differences in Axial Spondyloarthritis patients Pooled data from 3 Ixekizumab studies Women: 1⃣older at disease onset (30 vs. 26) 2⃣Longer symptom duration (17.8 yrs vs. 16.7 yrs) 3⃣More peripheral joint pain and lower HLA-B27 @RheumNow #ACR20 Abs#0876 https://t.co/qGHXApi0Ko

Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj

Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20

In SpA-paz cohort 80% of axSpA pts achieved R or LDA at one visit, but only 40% maintained this level of disease control. #ABS0893 #ACR20 @RheumNow https://t.co/3MKBKOoNSw https://t.co/pTMJhtfKbU

• Is It Feasible to Achieve Recommended Therapeutic Target Objective in Patients …

CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 week C-VIEW trial. #ABS0881 #ACR20 @RheumNow https://t.co/bNFHXbKEuF https://t.co/3Z232vKGPC

• Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis D…

SKIPPAIN trial: SEC showed rapid and significant improvement of spinal pain (primary endpt) and ⬇ disease activity in axSpA @RheumNow #ACR20 abs0899 #ACRbest https://t.co/fKSEjwd6i9

Do you consistently address T2T in your axSpA patients in your clinical practice? List your measures below! #ACR20 @RheumNow

T2T in clinical practice: Most axSpA pts had ≥1 annual ASDAS recorded, but target ID/LDA achieved in only 1/3 of pts at the first measurement. How do you address T2T in your practice? #ABS0879 #ACR20 @RheumNow https://t.co/Jy0mmqpHAb https://t.co/06fI10V3OZ

• Application of Treat-to-Target in Axial Spondyloarthritis in Daily Practice - A…

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @RheumNow and its Faculty.